Ondine Biomedical Inc (LSE:OBI) — Stock Price
Ondine Biomedical Inc (LSE:OBI) is currently trading at GBX13.75 GBX, up 1.85% today. Over the past 52 weeks, shares have ranged between GBX8.00 and GBX18.00. This page tracks Ondine Biomedical Inc's live share price on the LSE exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see market value of Ondine Biomedical Inc.
Ondine Biomedical Inc (OBI) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Ondine Biomedical Inc's daily closing share price and trading volume on the LSE exchange over the past year, giving a clear view of recent price momentum and liquidity.
Ondine Biomedical Inc Income Statement — Revenue, Profit & Earnings by Year
Ondine Biomedical Inc's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | GBX2.65 Million | GBX2.05 Million | GBX1.20 Million | GBX638.00K | GBX2.57 Million |
| Cost of Revenue | GBX1.56 Million | GBX728.00K | GBX500.00K | GBX351.00K | GBX1.31 Million |
| Gross Profit | GBX1.09 Million | GBX1.32 Million | GBX703.00K | GBX287.00K | GBX1.25 Million |
| Research & Development | GBX21.28 Million | GBX9.22 Million | GBX5.14 Million | GBX6.28 Million | GBX4.98 Million |
| SG&A | — | GBX9.93 Million | GBX8.01 Million | GBX10.91 Million | GBX12.97 Million |
| Total Operating Expenses | GBX31.13 Million | GBX20.77 Million | GBX15.51 Million | GBX19.05 Million | GBX18.77 Million |
| Operating Income | GBX-30.04 Million | GBX-19.44 Million | GBX-14.80 Million | GBX-18.76 Million | GBX-17.52 Million |
| EBITDA | GBX-29.45 Million | GBX-18.49 Million | GBX-13.79 Million | GBX-18.85 Million | GBX-48.36 Million |
| EBIT | GBX-30.04 Million | GBX-19.05 Million | GBX-14.37 Million | GBX-19.34 Million | GBX-48.87 Million |
| Interest Expense | GBX21.05K | GBX47.00K | GBX38.00K | GBX30.00K | GBX1.21 Million |
| Income Before Tax | GBX-29.59 Million | GBX-19.10 Million | GBX-14.41 Million | GBX-19.37 Million | GBX-50.09 Million |
| Income Tax Expense | — | — | GBX94.00K | GBX1.41 Million | GBX32.73 Million |
| Net Income | GBX-29.59 Million | GBX-19.10 Million | GBX-14.41 Million | GBX-19.37 Million | GBX-50.09 Million |
Ondine Biomedical Inc Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Ondine Biomedical Inc's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | GBX14.40 Million | GBX12.82 Million | GBX5.73 Million | GBX16.57 Million | GBX34.14 Million |
| Total Current Assets | GBX13.28 Million | GBX12.19 Million | GBX4.75 Million | GBX15.13 Million | GBX33.50 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | — | — | — | — | — |
| Net Receivables | GBX460.55K | GBX513.00K | GBX326.00K | GBX182.00K | GBX248.00K |
| Inventory | GBX1.82 Million | GBX1.27 Million | GBX1.07 Million | GBX1.29 Million | GBX1.06 Million |
| Property, Plant & Equipment | — | — | — | — | GBX601.00K |
| Goodwill | — | — | — | — | — |
| Total Liabilities | GBX10.91 Million | GBX5.95 Million | GBX3.65 Million | GBX4.92 Million | GBX4.48 Million |
| Total Current Liabilities | GBX10.81 Million | GBX5.95 Million | GBX3.49 Million | GBX3.91 Million | GBX3.92 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | GBX-10.17 Million | GBX-9.60 Million | GBX-2.44 Million | GBX-12.23 Million | GBX-29.63 Million |
| Total Stockholder Equity | GBX3.49 Million | GBX6.88 Million | GBX2.08 Million | GBX11.64 Million | GBX29.66 Million |
| Retained Earnings | GBX-315.33 Million | GBX-285.43 Million | GBX-266.33 Million | GBX-251.92 Million | GBX-232.54 Million |
Ondine Biomedical Inc Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Ondine Biomedical Inc generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | GBX-23.90 Million | GBX-15.49 Million | GBX-13.65 Million | GBX-16.34 Million | GBX-12.54 Million |
| Capital Expenditures | GBX117.29K | GBX10.00K | GBX177.00K | GBX311.00K | GBX77.00K |
| Free Cash Flow | GBX-24.02 Million | GBX-15.50 Million | GBX-13.83 Million | GBX-16.66 Million | GBX-12.62 Million |
| Investing Cash Flow | GBX-117.28K | GBX-10.00K | GBX-177.00K | GBX-311.00K | GBX-77.00K |
| Financing Cash Flow | GBX24.28 Million | GBX21.74 Million | GBX3.79 Million | GBX-275.00K | GBX41.90 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | GBX1.22 Million | GBX640.00K | GBX1.45 Million | GBX4.06 Million |
| Depreciation | GBX591.43K | GBX565.00K | GBX587.00K | GBX493.00K | GBX514.00K |
| Change in Cash | GBX406.14K | GBX6.79 Million | GBX-10.13 Million | GBX-16.60 Million | GBX29.24 Million |
Ondine Biomedical Inc Earnings History — EPS Actual vs. Analyst Estimates
Track Ondine Biomedical Inc's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Sep 26, 2025 | -0.03 | 0.00 | — |
| May 14, 2025 | -0.04 | 0.00 | — |
| Sep 30, 2024 | -0.03 | 0.00 | — |